Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2010

01.05.2010 | Epidemiology

IGF-I during primiparous pregnancy and maternal risk of breast cancer

verfasst von: Tianhui Chen, Annekatrin Lukanova, Kjell Grankvist, Anne Zeleniuch-Jacquotte, Marianne Wulff, Robert Johansson, Helena Schock, Per Lenner, Goran Hallmans, Goran Wadell, Paolo Toniolo, Eva Lundin

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Previously, we reported that insulin-like growth factor (IGF)-I during early pregnancy is positively associated with maternal risk of breast cancer. To further explore this association, we designed a new study limited to women who donated a blood sample during their first pregnancy ending with childbirth. A case–control study was nested within the Northern Sweden Maternity Cohort in which repository since 1975, serum specimens remaining after early pregnancy screening for infectious diseases had been preserved. Study subjects were selected among women who donated a blood sample during the full-term pregnancy that led to the birth of their first child. Two hundred and forty-four women with invasive breast cancer were eligible. Two controls, matching the index case for age and date at blood donation were selected (n = 453). IGF-I was measured in serum samples on an Immulite 2000 analyzer. Conditional logistic regression was used to estimate odds ratios and 95% confidence intervals. A significant positive association of breast cancer with IGF-I was observed, with OR of 1.73 (95% CI: 1.14–2.63) for the top tertile, P < 0.009. Subgroup analyses did not indicate statistical heterogeneity of the association by ages at sampling and diagnosis or by lag time to cancer diagnosis, although somewhat stronger associations with risk were observed in women ≤age 25 at index pregnancy and for cases diagnosed within 15 years of blood donation. The results of the study add further evidence for an adverse effect of elevated IGF-I concentrations during early reproductive life on risk of breast cancer.
Literatur
1.
Zurück zum Zitat Lukanova A, Toniolo P, Zeleniuch-Jacquotte A et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:2489–2493CrossRefPubMed Lukanova A, Toniolo P, Zeleniuch-Jacquotte A et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15:2489–2493CrossRefPubMed
2.
Zurück zum Zitat Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353CrossRefPubMed Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363:1346–1353CrossRefPubMed
3.
Zurück zum Zitat Fletcher O, Gibson L, Johnson N et al (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19PubMed Fletcher O, Gibson L, Johnson N et al (2005) Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 14:2–19PubMed
4.
Zurück zum Zitat Lukanova A, Andersson R, Wulff M et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case–control study. Am J Epidemiol 168:1284–1291CrossRefPubMed Lukanova A, Andersson R, Wulff M et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case–control study. Am J Epidemiol 168:1284–1291CrossRefPubMed
5.
Zurück zum Zitat Cnattingius S, Ericson A, Gunnarskog J, Kallen B (1990) A quality study of a medical birth registry. Scand J Soc Med 18:143–148PubMed Cnattingius S, Ericson A, Gunnarskog J, Kallen B (1990) A quality study of a medical birth registry. Scand J Soc Med 18:143–148PubMed
6.
Zurück zum Zitat Monaghan JM, Godber IM, Lawson N et al (2004) Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 41:220–226CrossRefPubMed Monaghan JM, Godber IM, Lawson N et al (2004) Longitudinal changes of insulin-like growth factors and their binding proteins throughout normal pregnancy. Ann Clin Biochem 41:220–226CrossRefPubMed
7.
Zurück zum Zitat Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577PubMed Caufriez A, Frankenne F, Hennen G, Copinschi G (1993) Regulation of maternal IGF-I by placental GH in normal and abnormal human pregnancies. Am J Physiol 265:E572–E577PubMed
8.
Zurück zum Zitat Richardson BE, Hulka BS, Peck JL et al (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727PubMed Richardson BE, Hulka BS, Peck JL et al (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727PubMed
9.
Zurück zum Zitat Cleveland WS, Loader C (1996) Smoothing by local regression: principles and methods. In: Schimek MG (ed) Statistical theory and computational aspects of smoothing, 1st edn. Springer, New York, pp 113–120 Cleveland WS, Loader C (1996) Smoothing by local regression: principles and methods. In: Schimek MG (ed) Statistical theory and computational aspects of smoothing, 1st edn. Springer, New York, pp 113–120
10.
Zurück zum Zitat Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665–1677CrossRefPubMed Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 10:1665–1677CrossRefPubMed
11.
Zurück zum Zitat Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47:209–217CrossRefPubMed Pollak MN (1998) Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47:209–217CrossRefPubMed
12.
Zurück zum Zitat Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6 Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6
13.
Zurück zum Zitat Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86:723–727CrossRefPubMed Clavel-Chapelon F (2002) Differential effects of reproductive factors on the risk of pre- and postmenopausal breast cancer. Results from a large cohort of French women. Br J Cancer 86:723–727CrossRefPubMed
14.
Zurück zum Zitat Jones RA, Moorehead RA (2008) The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 13:407–413CrossRefPubMed Jones RA, Moorehead RA (2008) The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 13:407–413CrossRefPubMed
15.
Zurück zum Zitat Rowzee AM, Lazzarino DA, Rota L, Sun Z, Wood TL (2008) IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia 13:361–370CrossRefPubMed Rowzee AM, Lazzarino DA, Rota L, Sun Z, Wood TL (2008) IGF ligand and receptor regulation of mammary development. J Mammary Gland Biol Neoplasia 13:361–370CrossRefPubMed
16.
Zurück zum Zitat Kleinberg DL, Wood TL, Furth PA, Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51–74CrossRefPubMed Kleinberg DL, Wood TL, Furth PA, Lee AV (2009) Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev 30:51–74CrossRefPubMed
17.
Zurück zum Zitat Loladze AV, Stull MA, Rowzee AM et al (2006) Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology 147:5412–5423CrossRefPubMed Loladze AV, Stull MA, Rowzee AM et al (2006) Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology 147:5412–5423CrossRefPubMed
18.
Zurück zum Zitat Bonnette SG, Hadsell DL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945CrossRefPubMed Bonnette SG, Hadsell DL (2001) Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. Endocrinology 142:4937–4945CrossRefPubMed
19.
Zurück zum Zitat Hall K, Enberg G, Hellem E et al (1984) Somatomedin levels in pregnancy: longitudinal study in healthy subjects and patients with growth hormone deficiency. J Clin Endocrinol Metab 59:587–594CrossRefPubMed Hall K, Enberg G, Hellem E et al (1984) Somatomedin levels in pregnancy: longitudinal study in healthy subjects and patients with growth hormone deficiency. J Clin Endocrinol Metab 59:587–594CrossRefPubMed
20.
Zurück zum Zitat Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone—a review. Placenta 23(Suppl A):S87–S94CrossRefPubMed Lacroix MC, Guibourdenche J, Frendo JL, Muller F, Evain-Brion D (2002) Human placental growth hormone—a review. Placenta 23(Suppl A):S87–S94CrossRefPubMed
21.
Zurück zum Zitat Eriksson L, Frankenne F, Eden S, Hennen G, von Schoultz B (1989) Growth hormone 24-h serum profiles during pregnancy—lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 96:949–953PubMed Eriksson L, Frankenne F, Eden S, Hennen G, von Schoultz B (1989) Growth hormone 24-h serum profiles during pregnancy—lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 96:949–953PubMed
22.
Zurück zum Zitat Hancock SL, Tucker MA, Hoppe RT (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31CrossRefPubMed Hancock SL, Tucker MA, Hoppe RT (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85:25–31CrossRefPubMed
23.
Zurück zum Zitat Ronckers CM, Erdmann CA, Land CE (2005) Radiation and breast cancer: a review of current evidence. Breast Cancer Res 7:21–32CrossRefPubMed Ronckers CM, Erdmann CA, Land CE (2005) Radiation and breast cancer: a review of current evidence. Breast Cancer Res 7:21–32CrossRefPubMed
24.
Zurück zum Zitat Grubbs CJ, Peckham JC, Cato KD (1983) Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administration. J Natl Cancer Inst 70:209–212PubMed Grubbs CJ, Peckham JC, Cato KD (1983) Mammary carcinogenesis in rats in relation to age at time of N-nitroso-N-methylurea administration. J Natl Cancer Inst 70:209–212PubMed
25.
Zurück zum Zitat Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49–61CrossRefPubMed Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 3:49–61CrossRefPubMed
26.
Zurück zum Zitat Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Cause Control 13:299–305CrossRef Liu Q, Wuu J, Lambe M, Hsieh SF, Ekbom A, Hsieh CC (2002) Transient increase in breast cancer risk after giving birth: postpartum period with the highest risk (Sweden). Cancer Cause Control 13:299–305CrossRef
27.
Zurück zum Zitat Pathak DR (2002) Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Cause Control 13:295–298CrossRef Pathak DR (2002) Dual effect of first full term pregnancy on breast cancer risk: empirical evidence and postulated underlying biology. Cancer Cause Control 13:295–298CrossRef
28.
Zurück zum Zitat Wood TL, Richert MM, Stull MA, Allar MA (2000) The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 5:31–42CrossRefPubMed Wood TL, Richert MM, Stull MA, Allar MA (2000) The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia 5:31–42CrossRefPubMed
29.
Zurück zum Zitat Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, Leroith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97:2225–2232CrossRefPubMed Neuenschwander S, Schwartz A, Wood TL, Roberts CT Jr, Hennighausen L, Leroith D (1996) Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 97:2225–2232CrossRefPubMed
30.
Zurück zum Zitat Schedin P (2006) Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6:281–291CrossRefPubMed Schedin P (2006) Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6:281–291CrossRefPubMed
Metadaten
Titel
IGF-I during primiparous pregnancy and maternal risk of breast cancer
verfasst von
Tianhui Chen
Annekatrin Lukanova
Kjell Grankvist
Anne Zeleniuch-Jacquotte
Marianne Wulff
Robert Johansson
Helena Schock
Per Lenner
Goran Hallmans
Goran Wadell
Paolo Toniolo
Eva Lundin
Publikationsdatum
01.05.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0519-6

Weitere Artikel der Ausgabe 1/2010

Breast Cancer Research and Treatment 1/2010 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.